Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD
Open Access
- 6 February 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Respiratory Research
- Vol. 18 (1), 31
- https://doi.org/10.1186/s12931-017-0512-2
Abstract
COPD often coexists with chronic conditions that may influence disease prognosis. We investigated associations between chronic (co)morbidities and exacerbations in primary care COPD patients. Retrospective cohort study based on 2012–2013 electronic health records from 179 Dutch general practices. Comorbidities from patients with physician-diagnosed COPD were categorized according to International Classification of Primary Care (ICPC) codes. Chi-squared tests, uni- and multivariable logistic, and Cox regression analyses were used to study associations with exacerbations, defined as oral corticosteroid prescriptions. Fourteen thousand six hundred three patients with COPD could be studied (mean age 67 (SD 12) years, 53% male) for two years. At baseline 12,826 (88%) suffered from ≥1 comorbidities, 3263 (22%) from ≥5. The most prevalent comorbidities were hypertension (35%), coronary heart disease (19%), and osteoarthritis (18%). Several comorbidities showed statistically significant associations with frequent (i.e., ≥2/year) exacerbations: heart failure (odds ratio [OR], 95% confidence interval: 1.72; 1.38–2.14), blindness & low vision (OR 1.46; 1.21–1.75), pulmonary cancer (OR 1.85; 1.28–2.67), depression 1.48; 1.14–1.91), prostate disorders (OR 1.50; 1.13–1.98), asthma (OR 1.36; 1.11–1.70), osteoporosis (OR 1.41; 1.11–1.80), diabetes (OR 0.80; 0.66–0.97), dyspepsia (OR 1.25; 1.03–1.50), and peripheral vascular disease (OR 1.20; 1.00–1.45). From all comorbidity categories, having another chronic respiratory disease beside COPD showed the highest risk for developing a new exacerbation (Cox hazard ratio 1.26; 1.17–1.36). Chronic comorbidities are highly prevalent in primary care COPD patients. Several chronic comorbidities were associated with having frequent exacerbations and increased exacerbation risk.Keywords
Funding Information
- GlaxoSmithKline (The Netherlands)
This publication has 32 references indexed in Scilit:
- Comorbidity in chronic obstructive pulmonary diseaseRespiratory Investigation, 2015
- Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and ManagementSeminars in Respiratory and Critical Care Medicine, 2015
- Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisThe Lancet Respiratory Medicine, 2015
- A Simplified Score to Quantify Comorbidity in COPDPLOS ONE, 2014
- Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTEThorax, 2014
- Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional studyBMC Family Practice, 2013
- Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional studyThe Lancet, 2012
- The influence of co-morbidity on health-related quality of life in asthma and COPD patientsRespiratory Medicine, 2003
- Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40Journal of Clinical Epidemiology, 2001